(Q53077187)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

title

A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

main subject

chronic myeloid leukemia

0 references

author

Junghoon Shin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Joo-Youn Cho

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Dong-Yeop Shin

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Doyeun Oh

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

Youngil Koh

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Seo Hyun Yoon

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Dae-Young Kim

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Kyoo-Hyung Lee

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Hyeong-Joon Kim

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Jae-Sook Ahn

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Yeo-Kyeoung Kim

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Jinny Park

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Sang-Kyun Sohn

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Joon Ho Moon

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Yoo Jin Lee

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Seonghae Yoon

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Jeong-Ok Lee

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

June-Won Cheong

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Kyoung Ha Kim

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Sung-Hyun Kim

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Hoon-Gu Kim

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Hawk Kim

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Seung-Hyun Nam

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Young Rok Do

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Sang-Gon Park

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Seong Kyu Park

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Sung Hwa Bae

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Hun Ho Song

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Min Kyoung Kim

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Chul Won Jung

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Seonyang Park

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Inho Kim

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

language of work or name

English

0 references

publication date

25 March 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

page(s)

1814-1823

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

21 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5943463

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5943463

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5943463

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5943463

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5943463

Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5943463

Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5943463

Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5943463

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5943463

Chronic myeloid leukemia in Asia

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5943463

Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5943463

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5943463

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5943463

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5943463

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5943463

Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5943463

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5943463

Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5943463

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5943463

Non-parametric inference for cumulative incidence functions in competing risks studies.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5943463

Prognostic discrimination in "good-risk" chronic granulocytic leukemia.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5943463

Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5943463

An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders

30 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29577674

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29577674

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Chronic myeloid leukaemia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29577674

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/CAM4.1450

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29577674%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference